Bindu Kanapuru

6PUBLICATIONS
46CO-AUTHORS
Data mining and knowledge discoveryMolecular medicineCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical bacteriology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 04, 2025
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma.

Poornima Sharma, Xue Lin, Zhenzhen Xu

|Oct 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.

Andrea C Baines, Bindu Kanapuru, Jay Zhao

|May 07, 2024
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.

Kavita Natrajan, Megha Kaushal, Bindu George

|Mar 09, 2023
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.

Andrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon

Pageof 1